# A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.

> **NCT06306560** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Harbin Medical University** · enrollment: 40 (estimated)

## Conditions studied

- Extensive-stage Small-cell Lung Cancer

## Interventions

- **DRUG:** adebrelimab
- **DRUG:** famitinib
- **DRUG:** chemotherapy

## Key facts

- **NCT ID:** NCT06306560
- **Lead sponsor:** Harbin Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-03-15
- **Primary completion:** 2027-03-15
- **Final completion:** 2027-04-15
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06306560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06306560, "A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06306560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*